Gynecomastia risk factors: Difference between revisions

	Gynecomastia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Gynecomastia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Gynecomastia risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Gynecomastia risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Gynecomastia risk factors
CDC on Gynecomastia risk factors
Gynecomastia risk factors in the news
Blogs on Gynecomastia risk factors
Directions to Hospitals Treating Gynecomastia
Risk calculators and risk factors for Gynecomastia risk factors

Revision as of 16:40, 18 May 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

The most potent risk factor in the development of gynecomastia is idiopathic often multifactorial.

↑ Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (1977). "Pathophysiology of spironolactone-induced gynecomastia". Ann Intern Med. 87 (4): 398–403. PMID 907238.
↑ Deepinder F, Braunstein GD (2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opin Drug Saf. 11 (5): 779–95. doi:10.1517/14740338.2012.712109. PMID 22862307.
↑ Braunstein GD (1993). "Gynecomastia". N Engl J Med. 328 (7): 490–5. doi:10.1056/NEJM199302183280708. PMID 8421478.

@@ Line 20: / Line 20: @@
 ** Anti-androgens
 ** Gonadotropin Releasing hormone (GNRH) agonists
-** 5-alpha reductase inhibitors
+** 5-alpha reductase inhibitors<ref name="pmid22862307">{{cite journal| author=Deepinder F, Braunstein GD| title=Drug-induced gynecomastia: an evidence-based review. | journal=Expert Opin Drug Saf | year= 2012 | volume= 11 | issue= 5 | pages= 779-95 | pmid=22862307 | doi=10.1517/14740338.2012.712109 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22862307  }} </ref>
 ** Ketoconazole
 ** steroids